ArticleToxics2023
Enhanced Gastric/Lung Arsenic Bioaccessibility from Lignite Fly Ashes: Comparing Bioaccessibility Rates with Multiple Environmental Matrices.
Article in Toxics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inorganic arsenic (As), a carcinogenic element to humans, is among the most dangerous and flammable substances that coal-burning plants could release. When coal is burned, large portions of arsenic are captured on fly-ash (FA) particles, but it could also contribute significantly to stack emissions of fine fly-ash particles. The aim of this study was to evaluate the oral and respiratory bioaccessibility of arsenic in lignite fly-ash (LFA) samples, and their contribution to total As exposure. Arsenic bioaccessibility fractions via ingestion and inhalation showed significant differences, suggesting the presence of highly soluble As-bearing phases in the studied LFA samples. The bioaccessible As fractions (BAF%) in the simulated gastric fluids (UBM protocol, ISO 17924:2018) showed a range of 45-73%, while the pulmonary bioaccessibility rates in the simulated lung fluid (artificial lung fluid (ALF)) exhibited significantly enhanced levels ranging from 86% to 95%. The obtained arsenic bioaccessibility rates were compared with previous data for multiple environmental matrices such as soil and dust-related materials, revealing that LFA exhibited significantly higher bioaccessibility (%) for the inhalation pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.